Aardvark Therapeutics (NASDAQ:AARD) Releases Earnings Results

Aardvark Therapeutics (NASDAQ:AARD) posted its earnings results on Thursday. The company reported ($0.99) earnings per share (EPS) for the quarter, FiscalAI reports.

Aardvark Therapeutics Price Performance

Shares of Aardvark Therapeutics stock traded down $0.29 on Thursday, hitting $5.60. 126,183 shares of the company’s stock traded hands, compared to its average volume of 147,346. The firm’s 50-day moving average price is $5.31 and its two-hundred day moving average price is $9.99. The stock has a market capitalization of $122.19 million, a PE ratio of -1.91 and a beta of 5.11. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $17.94.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AARD. Stifel Nicolaus reiterated a “hold” rating and issued a $6.00 target price (down from $24.00) on shares of Aardvark Therapeutics in a research note on Monday, March 2nd. BTIG Research reiterated a “buy” rating and issued a $9.00 target price on shares of Aardvark Therapeutics in a research note on Tuesday, March 24th. Morgan Stanley reiterated an “equal weight” rating and issued a $7.00 target price (down from $29.00) on shares of Aardvark Therapeutics in a research note on Monday, March 2nd. Oppenheimer cut their target price on shares of Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Finally, B. Riley Financial began coverage on shares of Aardvark Therapeutics in a research note on Wednesday, January 28th. They issued a “buy” rating and a $32.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Institutional Trading of Aardvark Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in AARD. Goldman Sachs Group Inc. bought a new stake in shares of Aardvark Therapeutics during the 1st quarter valued at $153,000. Geode Capital Management LLC raised its position in shares of Aardvark Therapeutics by 129.7% during the 2nd quarter. Geode Capital Management LLC now owns 136,927 shares of the company’s stock valued at $1,851,000 after acquiring an additional 77,327 shares during the last quarter. New York State Common Retirement Fund bought a new stake in shares of Aardvark Therapeutics during the 2nd quarter valued at $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Aardvark Therapeutics during the 2nd quarter valued at $42,000. Finally, Bank of America Corp DE raised its position in shares of Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after acquiring an additional 3,369 shares during the last quarter.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.